My experience with clinical trials (currently HCV, HBV, IBD) is that hospitals are paid an amount per patient to account for additional costs in patient management that are caused by the trial - extra visits, staff time etc. Typically that is in the order of $2000 to $5000 per patient recruited. It is most likely as you say that the EUS and CT costs are part of the ongoing patient care and would be paid for by the hospital/insurer. In terms of a pivotal trial itself, it would be most likely considered unethical to have a placebo arm, so the control arm will be standard of care e.g. gemcitabine or FOLFOX.
OSL Price at posting:
8.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)